

Congress of the United States
House of Representatives

COMMITTEE ON OVERSIGHT AND ACCOUNTABILITY

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
MINORITY (202) 225-5051

<https://oversight.house.gov>

MEMORANDUM

July 21, 2023

To: Members, Subcommittee on Health Care and Financial Services

From: Committee Staff

Re: Hearing titled “Hemp in the Modern World: The Yearslong Wait for FDA Action”

On Thursday, July 27, 2023, at 2:00 p.m. ET, in room 2247 of the Rayburn House Office Building, the Oversight and Accountability Subcommittee on Health Care and Financial Services will host a hearing titled “Hemp in the Modern World: The Yearslong Wait for FDA Action.”

I. BACKGROUND:

The 2018 Farm Bill legalized the growing and selling of hemp and removed products containing cannabidiol (CBD) from being classified as Schedule I controlled substances under the Controlled Substance Act. Since that time, the Food and Drug Administration (FDA) has failed to regulate hemp-derived products under existing legal authorities such as those pertaining to foods and dietary supplements, and publicly took a position earlier this year that a new regulatory pathway for CBD products is necessary.

II. HEARING PURPOSE:

The hearing will examine whether hemp-derived products such as CBD are appropriate for regulation under existing legal pathways provided by the Federal Food, Drug, and Cosmetic Act, and the impact FDA’s failure to regulate may have for markets and consumers.

III. WITNESSES:

Jonathan S. Miller

General Counsel

U.S. Hemp Roundtable

Rayetta G. Henderson, Ph.D.

Senior Managing Scientist

ToxStrategies, LLC

Richard A. Badaracco

President-Elect, Kentucky Narcotic Officers Association

(Retired) Assistant Special Agent in Charge, U.S. Drug Enforcement Administration